Building Blocks of IP

For any life sciences startup, understanding intellectual property begins with three foundational concepts: patents, trademarks, and trade secrets. While each protects something different, together they form a toolkit that allows companies to safeguard their innovations, build their brand, and maintain competitive advantages. At their core, intellectual property laws exist to solve a practical problem – they give innovators and business a legal mechanism to benefit from their own creativity and investment, rather than seeing that work freely copied by others. For startups operating in life sciences, where the gap between a promising discovery and a commercially viable product can span many years and enormous expense, understanding which tool applies in which situation is an essential skill.

Three Types of Protection, Three Different Purposes

A patent is a government-granted right that gives its owner exclusive control over a specific invention for a limited period, generally 20 years from the date of filing, whether that is a new drug compound, a manufacturing process, a medical device, or a diagnostic method. In exchange for this exclusivity, the inventor must publicly disclose how the invention works, a trade-off that advances scientific knowledge while rewarding innovation. A trademark, by contrast, protects identifiers of commercial origin – brand names, logos, and slogans – that distinguish one company’s products or services from another’s. Where a patent protects what a product is, a trademark protects what a product is called and how it is recognized in the marketplace. A trade secret is perhaps the most intuitive of the three: it is any confidential business information that provides a competitive edge, from a proprietary formula or manufacturing process to a customer list or internal algorithm. Unlike patents and trademarks, trade secrets require no government registration – they are protected simply by being kept secret, typically through confidentiality agreements and internal security practices.

Patents as Currency in Early-Stage Fundraising

In the early stages of a startup’s life – pre-seed, seed, and Series A rounds – investors are asked to fund ideas and potential rather than proven products. In this environment, a strong patent portfolio is one of the most persuasive signals a founder can send. It tells investors that the core science has been independently assessed as novel and nonobvious, that competitors face meaningful legal barriers to copying the approach, and that the company has taken concrete steps to protect its future revenue. Angel investors and early-stage venture capital firms routinely scrutinize the IP landscape before committing funds: Is the key technology protected? Are there gaps that a competitor could exploit? Does the startup have freedom to operate in the field? Answering these questions favorably can be the difference between closing a round and losing one.

Sustaining Momentum Through Later Funding and Partnerships

As a startup matures and pursues larger funding rounds – Series B, C, and beyond – or seeks partnerships with larger pharmaceutical or medical device companies, the stakes around IP only increase. At these stages, institutional investors and potential partners will conduct thorough due diligence, and a well-structured, defensible patent portfolio can significantly increase a company’s valuation and negotiating power. Conversely, gaps in IP protection, ownership disputes, or poorly drafted patents can derail deals entirely. Licensing agreements, co-development partnerships, and eventual acquisition offers are all shaped by the strength and scope of a startup’s patent position. For life sciences companies, where regulatory approval timelines are long and market exclusivity windows are finite, building and maintaining a thoughtful patent strategy from day one is not a luxury – it is a fundamental business imperative.

Choosing the Right Tool – and Why It Matters Early

The distinctions between these three forms of IP protection are not merely academic. They carry real strategic consequences, particularly for early-stage companies that may have limited resources and only one chance to protect a core innovation correctly. A startup that relies on trade secret protection for an invention it should have patented may find itself unprotected the moment a competitor independently develops the same technology and files first. Equally, a company that neglects trademark protection in its early years can find its brand diluted or contested just as it begins to gain market traction. The chapters that follow will explore each of these IP tools in greater depth, with a focus on how life sciences startups can use them strategically as they grow from early discovery through funding, partnership, and beyond.

This article is part of our Life Sciences Startup IP Resource Center.